Side-by-side · Research reference

KPVvsTirzepatide

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongDraft13/39 cited

BFDA-ApprovedVerified14/45 cited

KPV

α-MSH C-terminal · Anti-inflammatory

200–500 mcgDaily doseDalle-Pang 2024

AnimalEvidence levelDalle-Pang 2024

HoursHalf-life (est)

SQ / oral / topical · Local · Daily or 2-3×/week

Tirzepatide

GIP+GLP-1 Dual Agonist · FDA-Approved

2.5–15 mgWeekly doseZEPBOUND (tirzepatide) injecti 2023

20.9%Body-weight ↓Jastreboff 2022

~5 daysHalf-lifeZEPBOUND (tirzepatide) injecti 2023

SQ · Abdomen / thigh / arm · Once weekly

01Mechanism of Action

Parameter

KPV

Tirzepatide

Primary target

Intracellular targets bypassing melanocortin receptors (proposed)Dalle-Pang 2024

GIP receptor (GIPR) + GLP-1 receptor (GLP-1R)Frias 2018

Pathway

NF-κB inhibition + cytokine modulation (TNF-α, IL-1β, IL-6) → reduced inflammationDalle-Pang 2024

Dual GIPR/GLP-1R agonism → ↑insulin (glucose-dependent), ↓glucagon, ↓gastric emptying, ↓appetite, ↑energy expenditure (via GIP component)Jastreboff 2022 Frias 2018

Downstream effect

Anti-inflammatory action without α-MSH pigmentation effects; gut barrier protectionDalle-Pang 2024

Profound glycemic improvement and weight reduction; cardiometabolic benefitsJastreboff 2022

Feedback intact?

No melanocortin receptor binding

Glucose-dependent insulin release preserves physiological feedback

Origin

Synthetic tripeptide; the C-terminal Lys-Pro-Val residues of α-MSH (residues 11-13)Dalle-Pang 2024

39-AA peptide with C-20 fatty-acid acylation. Single molecule with balanced GIP + GLP-1 affinityFrias 2018

Antibody development

—

02Dosage Protocols

Parameter

KPV

Tirzepatide

Standard dose

200–500 mcg / day SQ or oralDalle-Pang 2024

—

Frequency

Daily or 2–3× per week

—

Lower / starter dose

100 mcg / day

—

Evidence basis

Animal-strong + emerging clinical data in IBDDalle-Pang 2024

FDA-approved · Phase 3 RCTs (SURMOUNT, SURPASS)Jastreboff 2022 ZEPBOUND (tirzepatide) injecti 2023

Duration

4–8 weeks per cycle

Indefinite for chronic indication

Reconstitution

Bacteriostatic water (SQ form)

Pre-filled commercial pen. Research vial: bacteriostatic water per label.

Timing

No specific time; often taken with / before meals (oral)

Once weekly, any time of day

Half-life

Hours (estimated; rapid tissue uptake)

~5 days (116 h)ZEPBOUND (tirzepatide) injecti 2023

Standard dose (T2D)

—

5–15 mg / weekZEPBOUND (tirzepatide) injecti 2023

Standard dose (weight)

—

5, 10, or 15 mg / week (titrated)ZEPBOUND (tirzepatide) injecti 2023 Jastreboff 2022

Titration schedule

—

2.5 mg → +2.5 mg every 4 weeks → 15 mg max

Slower titration mitigates GI side effects.

04Side Effects & Safety

Parameter

KPV

Tirzepatide

Injection site reaction

Mild irritation

Mild erythema, pruritus

GI symptoms

Rare nausea (oral form)

Nausea, vomiting, diarrhea (common, dose-dependent)Jastreboff 2022

Pigmentation

None (unlike full α-MSH)Dalle-Pang 2024

—

Long-term safety

Limited human data

—

Pregnancy / OB

Avoid — insufficient data

Contraindicated

Pancreatitis risk

—

Rare; discontinue if suspectedZEPBOUND (tirzepatide) injecti 2023

Thyroid C-cell tumours

—

Boxed warning — contraindicated in MEN2 / MTC historyZEPBOUND (tirzepatide) injecti 2023

Hypoglycemia

—

Low as monotherapy; risk with sulfonylureas / insulin

Gallbladder events

—

Increased cholelithiasis

Diabetic retinopathy

—

Rapid glycemic improvement may transiently worsen

Absolute Contraindications

KPV

·Pregnancy / breastfeeding

Tirzepatide

·MTC personal or family history; MEN2
·Pregnancy / breastfeeding
·Hypersensitivity to tirzepatide

Relative Contraindications

KPV

·Active autoimmune disease (theoretical)

Tirzepatide

·Severe gastroparesis
·History of pancreatitis
·Diabetic retinopathy

05Administration Protocol

Parameter

KPV

Tirzepatide

1. Reconstitution

Add 1 mL bacteriostatic water to vial per labelling.

Commercial: pre-filled pen / vial. Research lyophilised: bacteriostatic water per label.

2. Form

SQ injection (acute), oral capsule (chronic / gut), topical for skin indications.

SQ — abdomen, thigh, or upper arm. Rotate weekly.

3. Timing

Morning preferred; oral form taken with / before meals.

Once weekly, same day. Day change allowed if ≥3 days separate doses.

4. Storage

Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.

Refrigerate 2–8 °C unopened. Room temp ≤30 °C up to 21 days after first use.

5. Needle

29–31G insulin syringe (SQ form).

Pen-supplied. Research vial: 27–31G insulin syringe.

06Stack Synergy

KPV

+ BPC-157

Strong

View BPC-157 →

KPV (NF-κB inhibition, cytokine reduction) + BPC-157 (VEGF-driven angiogenesis, tissue regeneration) form the classic gut-healing stack. KPV reduces inflammatory drive; BPC-157 promotes mucosal repair. Anecdotally favoured for IBD, ulcerative colitis, and post-surgical gut recovery.

KPV: 200–500 mcg oral · daily
BPC-157: 250–500 mcg oral or SQ · daily
Primary benefit: Combined anti-inflammation + mucosal repair for gut conditions

Dalle-Pang 2024 Sikiric 2018

Tirzepatide

— no documented stacks